Nikos Pekiaridis | Nurphoto | Getty Images
Moderna surprised investors by reporting a profit for the quarter, despite a decrease in sales of its Covid vaccine, which is its only product. The company’s financial performance reflects the challenges faced by Covid vaccine manufacturers as the demand for protective shots and treatments declined with the easing of the pandemic.
Here are the key figures for Moderna’s fourth-quarter results compared to analysts’ expectations:
Earnings per share: 55 cents, exceeding the anticipated loss of 97 cents. Revenue: $2.81 billion, surpassing the projected $2.50 billion.
Moderna’s net income for the fourth quarter was $217 million, or 55 cents per share, compared to $1.47 billion, or $3.61 per share, in the same period last year.
The company’s sales for the fourth quarter…
2024-02-22 06:34:58
Read more on www.cnbc.com